For citations:
Frolova MA, Glazkova EV, Stenina MB. PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice. Meditsinskiy sovet = Medical Council. 2020;(9):57-61. (In Russ.) https://doi.org/10.21518/2079-701X-2020-9-57-61